COPD: Symptoms, Spirometry, Inhalers and GOLD 2026 Treatment Guidelines

Evidence reviewed: 9 November 2026. Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition involving persistent respiratory symptoms and airflow obstruction caused by abnormalities of the airways and/or alveoli. Common symptoms include chronic cough, sputum production, breathlessness and reduced exercise tolerance. Spirometry after bronchodilator administration is essential to confirm persistent obstruction; symptoms or smoking history alone are insufficient. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 report made major changes to its A/B/E patient groups: one moderate or severe exacerbation in the previous year now places treatment-naive patients in Group E, highlighting the need to prevent future episodes. It also updated recommendations on biologics, exacerbation assessment and multimorbidity [1–4].

What happens in COPD?

COPD develops through interacting small-airway disease, chronic inflammation, mucus changes and loss of alveolar structure. Some patients primarily have emphysema, with destruction of alveolar walls and reduced elastic recoil; others have more prominent chronic bronchitic symptoms such as cough and sputum. Most have varying contributions from several processes [1,2].

Airflow obstruction is persistent but not necessarily completely irreversible. Significant bronchodilator responsiveness may occur in COPD, and asthma and COPD can coexist. A person with COPD may experience meaningful improvement in symptoms and lung function after treatment even if the spirometric ratio remains below the diagnostic threshold.

Causes and risk factors

  • Tobacco smoke exposure, including cigarettes and other smoked products.
  • Indoor biomass smoke from poorly ventilated cooking or heating fuels.
  • Occupational dust, fumes and chemical exposures.
  • Outdoor air pollution and other harmful environmental exposures.
  • Genetic risk, notably alpha-1 antitrypsin deficiency (AATD).
  • Abnormal lung growth, recurrent childhood respiratory illness or other developmental factors.

Not everyone with COPD has smoked. People with significant biomass exposure, occupational hazards or inherited conditions may develop obstruction, and blaming patients can delay care. GOLD recommends considering AATD testing in every patient diagnosed with COPD, subject to locally available testing [1].

Common symptoms and signs

Typical findings include progressively limiting exertional breathlessness, chronic cough, sputum production, wheeze and recurrent chest infections. Symptoms may fluctuate, and some people reduce their activities unconsciously to avoid breathlessness. More advanced disease can cause weight loss, muscle weakness, exercise intolerance and hypoxemia [1].

Possible alternative or coexisting causes include asthma, heart failure, anemia, bronchiectasis, interstitial lung disease and pulmonary embolism. New chest pain, rapidly worsening breathlessness or syncope should not automatically be attributed to COPD.

How is COPD diagnosed?

In a person with compatible symptoms and exposure risks, GOLD requires post-bronchodilator FEV1/FVC below 0.70 on quality-assured spirometry to establish persistent airflow obstruction [1,2]. FEV1 is forced expiratory volume during the first second, while FVC is total forced vital capacity during a forced exhalation.

The fixed ratio can overdiagnose obstruction in some older people and underdiagnose it in some younger adults compared with the lower limit of normal, so clinical context, test quality and repeat testing near the cutoff are important. Peak flow or a CT scan alone cannot replace confirmatory spirometry in a typical case.

GOLD spirometric grades and symptom groups are different

FEV1-based spirometric grade Post-bronchodilator FEV1 percent predicted
GOLD 1 80% or higher
GOLD 2 50–79%
GOLD 3 30–49%
GOLD 4 Below 30%

GOLD 1–4 reflects the degree of airflow obstruction, while the A/B/E grouping guides initial pharmacologic therapy based on symptoms and recent exacerbations. A patient with modest airflow limitation can have repeated exacerbations, and a patient with severe obstruction may report few symptoms because activity has been reduced [1,3].

GOLD 2026: the A/B/E classification changed

The 2026 GOLD update recognizes that even one moderate exacerbation increases future exacerbation risk. Under the revised initial treatment scheme:

Group 2026 criteria for treatment-naive patients General initial inhaler approach
A No moderate/severe exacerbation in previous year and relatively low symptom burden. A suitable bronchodilator; choose short- or long-acting based on symptom frequency.
B No moderate/severe exacerbation in previous year and greater symptom burden. Usually dual LABA + LAMA long-acting bronchodilation.
E At least one moderate or severe exacerbation in the prior year, regardless of symptom score. Usually LABA + LAMA; consider selected triple therapy where eosinophils are at least 300 cells/µL.

This corrects the outdated threshold of two or more moderate exacerbations for Group E. The initial A/B/E algorithm applies to people not already taking maintenance therapy; patients on existing inhalers are managed through GOLD’s follow-up pathways according to persistent dyspnea or exacerbations [1,3].

Short-acting versus long-acting bronchodilators

Short-acting bronchodilators such as salbutamol/albuterol (SABA) and ipratropium (SAMA) provide relief during intermittent symptoms or exacerbations. Long-acting beta2 agonists (LABA) and long-acting muscarinic antagonists (LAMA) improve sustained bronchodilation and daily function [1].

Class Examples Role and safety considerations
SABA Salbutamol/albuterol Rapid symptom relief; tremor, palpitations or hypokalemia with excessive use.
SAMA Ipratropium Short-acting antimuscarinic relief; dry mouth and eye exposure precautions.
LABA Formoterol, indacaterol, olodaterol, salmeterol Long-acting bronchodilation; usually used in appropriate maintenance combinations.
LAMA Tiotropium, umeclidinium, glycopyrronium Long-acting reduction of cholinergic bronchoconstriction; dry mouth/urinary effects.
LABA + LAMA Umeclidinium/vilanterol, tiotropium/olodaterol, others Preferred dual maintenance bronchodilation for many symptomatic or exacerbation-prone patients.

Inhaler choice depends on technique, access, dexterity, inspiratory flow and device preference. A patient may benefit more from correcting poor technique than from adding multiple medicines to a regimen that is not delivered to the lungs effectively.

When should inhaled corticosteroids be used?

Inhaled corticosteroids (ICS) reduce exacerbations in selected COPD populations, especially with higher blood eosinophil counts, but they are not routine monotherapy for COPD. They are often used in triple therapy (LABA + LAMA + ICS) when exacerbation risk and biomarker profile justify them [1,3].

Blood eosinophils guide the probability of benefit, not a rigid all-or-nothing diagnosis. A response is more likely at 300 cells/µL or greater, while many patients with 100 cells/µL or greater and ongoing exacerbations despite dual bronchodilation may benefit. When eosinophils are below 100 cells/µL, ICS benefit is generally less likely [1].

Risks include pneumonia, oral candidiasis, hoarseness and other steroid-related effects. If a person has concomitant asthma, an ICS-containing regimen is important according to asthma guidance; bronchodilator-only COPD pathways should not override established asthma care.

Follow-up treatment: persistent dyspnea versus exacerbations

For a patient on initial treatment who remains breathless, first reassess inhaler technique, adherence, activity limitations and coexisting cardiac or pulmonary disease. Escalating from one long-acting bronchodilator to LABA + LAMA may help persistent dyspnea [1,3].

For a patient with further moderate/severe exacerbations despite dual bronchodilation, GOLD 2026 suggests considering LABA + LAMA + ICS, especially when blood eosinophils are at least 100 cells/µL. A higher eosinophil count predicts a greater expected response. Prior pneumonia, recurrent infection or low eosinophils may change the balance of benefits and harms.

Newer options: PDE inhibitors and biologic therapy

Patients with ongoing exacerbations despite optimized inhaled treatment may require specialist consideration of additional agents. Roflumilast, an oral phosphodiesterase-4 inhibitor, may be used in selected patients with FEV1 below 50% predicted, chronic bronchitis and relevant severe exacerbation history; adverse effects can include diarrhea, weight loss and mood changes [1].

Ensifentrine is an inhaled dual PDE3/PDE4 inhibitor available in some jurisdictions for COPD maintenance, with clinical benefits for lung function and symptoms in selected patients. It is not a substitute for diagnosing COPD, teaching device use or optimizing indicated standard inhalers.

GOLD 2026 biologic updates: dupilumab and mepolizumab

GOLD 2026 added a specific biologic treatment pathway for selected patients with ongoing exacerbations on triple inhaled therapy and an eosinophilic phenotype. Dupilumab targets IL-4 receptor alpha signaling, while mepolizumab targets IL-5. These are not standard first-line COPD medicines [1,3].

In a patient receiving LABA + LAMA + ICS who continues to exacerbate and has blood eosinophils at least 300 cells/µL, GOLD includes dupilumab for those with chronic bronchitis features and mepolizumab in eligible eosinophilic disease, subject to product-specific indications and local regulatory authorization. Biologic therapy should be supervised by a specialist and does not replace smoking cessation or inhaler optimization.

COPD exacerbation: recognizing sudden worsening

An exacerbation is an acute worsening of dyspnea, cough and/or sputum beyond usual daily variation, often triggered by infection, pollution or other stressors. Not every worsening episode is COPD; pneumonia, heart failure, pulmonary embolism, pneumothorax and myocardial ischemia can mimic or coexist with an exacerbation [1].

Emergency features include severe respiratory distress, marked hypoxemia, new confusion, cyanosis, inability to speak in full sentences, chest pain, collapse or major drowsiness. Call emergency services or seek urgent hospital care.

How exacerbations are treated

Depending on severity, management may include increased short-acting bronchodilators, oxygen titration, a short course of systemic corticosteroid and antibiotics when a bacterial component is likely. GOLD 2026 places greater emphasis on assessing severity using clinical criteria from the Rome proposal, rather than defining severity only by what treatment or healthcare setting was used [1,3].

Intervention Usual role Important qualification
Short-acting inhaled bronchodilators First-line relief of acute airflow obstruction. Assess delivery device, technique and response.
Systemic corticosteroids Often a short course (commonly 5 days) in suitable moderate/severe exacerbations. Monitor glucose, infection and other adverse effects; not a long-term daily COPD default.
Antibiotics For selected exacerbations with purulent sputum, evidence of bacterial infection or ventilatory support needs. Not prescribed automatically for every COPD flare.
Controlled oxygen For documented hypoxemia. Often target SpO2 88–92% during hypercapnia-risk exacerbation management, with blood gas review.
Noninvasive ventilation For selected acute hypercapnic respiratory failure. Requires monitored medical setting and appropriate contraindication review.

Patients should not automatically take leftover antibiotics or double chronic oral steroids for every bout of increased cough. A clinician-directed rescue plan can be appropriate for selected people after education and follow-up [1].

Long-term oxygen therapy

Long-term oxygen therapy (LTOT) can improve survival in patients with severe chronic resting hypoxemia meeting established criteria. It is not routinely indicated solely because a person feels breathless with normal resting oxygenation. Prescribing involves appropriate measurements under stable conditions and reassessment after an acute exacerbation [1].

Supplemental oxygen carries fire risk, especially around smoking or open flames. Patients should receive clear oxygen-safety education and avoid smoking during oxygen use.

Smoking cessation: the highest-value intervention

Stopping smoking slows the accelerated loss of lung function and benefits survival in patients who smoke. Evidence-based strategies include behavioral support and suitable pharmacotherapy, such as nicotine-replacement products, varenicline or bupropion where appropriate, with careful attention to local availability and contraindications [1].

Patients who have never smoked need equally serious assessment of biomass, occupational and environmental exposures. Indoor air quality, workplace protective measures and reduction of dust or fumes matter for long-term control.

Pulmonary rehabilitation and physical activity

Pulmonary rehabilitation is a structured program combining exercise training, education, breathing strategies and self-management support. It can improve breathlessness, exercise tolerance and quality of life, including after hospitalization for exacerbations. Maintaining activity also helps prevent deconditioning [1].

Rehabilitation should be adapted to oxygenation, comorbid cardiac disease, mobility, nutritional status and patient capacity. Breathing exercises alone do not replace prescribed maintenance inhalers, but can support symptom management and anxiety reduction.

Vaccinations for COPD

COPD increases vulnerability to some respiratory infections. GOLD 2026 highlights appropriate vaccination against influenza, pneumococcus, COVID-19 and respiratory syncytial virus (RSV), plus other age/risk-appropriate immunizations such as pertussis and shingles according to local national guidance [1].

Vaccine eligibility changes by age, immune status, season and country. Patients should review current schedules rather than assuming a single influenza or pneumococcal product applies to everyone.

Cardiovascular disease and other COPD comorbidities

People with COPD frequently have heart disease, hypertension, osteoporosis, depression, anxiety, sleep apnea, lung cancer risk and metabolic disease. GOLD 2026 expanded its multimorbidity discussion, including the relationship between exacerbations and cardiovascular complications [1,3].

Heart failure can mimic worsening COPD, while an inhaler side effect can also resemble palpitations from arrhythmia. Evaluate new swelling, chest pain or severe exercise intolerance appropriately rather than reflexively escalating respiratory medicine.

Inhaler technique: a frequently missed cause of poor control

Poor device technique can lead to inadequate medicine delivery despite an appropriate prescription. Clinicians should observe inhaler use at diagnosis and follow-up: dry-powder inhalers need adequate inspiratory flow, while metered-dose inhalers require coordinated inhalation or an appropriate spacer. Cleaning and preparation procedures depend on the device [1].

If the patient continues to exacerbate, assess adherence, affordability, inhaler technique, correct diagnosis, oxygen status and other conditions before assuming drug failure.

Practical examples

Patient with breathlessness but no recent exacerbation

An older adult with confirmed COPD, substantial activity-limiting breathlessness and no moderate or severe exacerbation in the prior year may fall into GOLD 2026 Group B. Appropriate initial treatment commonly involves LABA + LAMA, alongside smoking/exposure assessment, vaccination and rehabilitation. An ICS should not be added automatically because the patient is breathless [1].

Patient with one treated exacerbation in the last year

A patient who required prescribed systemic steroids for one moderate COPD exacerbation in the past 12 months can now fall into Group E under GOLD 2026, even if the symptom score is modest. Initial therapy often involves LABA + LAMA; high blood eosinophils and other circumstances may justify considering ICS-containing triple treatment [1,3].

Frequently asked questions

Can COPD be diagnosed without spirometry?

Not reliably. GOLD requires post-bronchodilator airflow obstruction in the appropriate clinical context [1].

Is COPD always irreversible?

Airflow limitation tends to persist, but bronchodilator responsiveness and clinical improvement are possible.

Did GOLD 2026 change Group E?

Yes. One moderate or severe exacerbation in the previous year now qualifies for Group E in the initial A/B/E framework [1,3].

Does everyone with COPD need inhaled steroids?

No. ICS is selected based on exacerbation risk, blood eosinophils and asthma features, weighing pneumonia risk.

Are dupilumab and mepolizumab first-line COPD medicines?

No. They are specialist biologic options for selected eosinophilic, exacerbation-prone patients despite appropriate inhaled treatment.

Should antibiotics be given for every increase in cough?

No. They are reserved for situations suggesting bacterial exacerbation or other specific indications.

Key takeaways

COPD diagnosis requires quality-assured post-bronchodilator spirometry. GOLD 2026 classifies a treatment-naive patient with one moderate or severe exacerbation as Group E. LABA + LAMA is a mainstay for many symptomatic patients; ICS and biologics require selective, often eosinophil-guided decisions. Smoking cessation, pulmonary rehabilitation, vaccination and early management of exacerbations remain essential.

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2026 report and pocket guide. GOLD; 2026.
  2. World Health Organization. Chronic obstructive pulmonary disease (COPD): fact sheet. WHO; accessed 9 Nov 2026.
  3. Hillas G, Gogali A, Loukides S, Kostikas K. GOLD 2026 report: what is new and noteworthy for the practicing clinician. COPD. 2026;23(1). doi:10.1080/15412555.2026.2622744.
  4. Global Initiative for Chronic Obstructive Lung Disease. GOLD: current reports, diagnosis and treatment resources. Accessed 9 Nov 2026.
  5. Centers for Disease Control and Prevention. About chronic obstructive pulmonary disease. CDC; accessed 9 Nov 2026.

Medical disclaimer: Educational material only. COPD diagnosis and inhaler, steroid, antibiotic, biologic and oxygen decisions require professional assessment and local guidance. Severe breathlessness, chest pain, blue/gray discoloration, confusion or collapse is a medical emergency.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *